• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过蛋白质组学发现和验证肌萎缩侧索硬化症的生物标志物。

Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.

机构信息

Department of Pathology, University of Pittsburgh School of Medicine, BST S-420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA.

出版信息

Muscle Nerve. 2010 Jul;42(1):104-11. doi: 10.1002/mus.21683.

DOI:10.1002/mus.21683
PMID:20583124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2975276/
Abstract

Recent studies using mass spectrometry have discovered candidate biomarkers for amyotrophic lateral sclerosis (ALS). However, those studies utilized small numbers of ALS and control subjects. Additional studies using larger subject cohorts are required to verify these candidate biomarkers. Cerebrospinal fluid (CSF) samples from 100 patients with ALS, 100 disease control, and 41 healthy control subjects were examined by mass spectrometry. Sixty-one mass spectral peaks exhibited altered levels between ALS and controls. Mass peaks for cystatin C and transthyretin were reduced in ALS, whereas mass peaks for posttranslational modified transthyretin and C-reactive protein (CRP) were increased. CRP levels were 5.84 +/- 1.01 ng/ml for controls and 11.24 +/- 1.52 ng/ml for ALS subjects, as determined by enzyme-linked immunoassay. This study verified prior mass spectrometry results for cystatin C and transthyretin in ALS. CRP levels were increased in the CSF of ALS patients, and cystatin C level correlated with survival in patients with limb-onset disease. Our biomarker panel predicted ALS with an overall accuracy of 82%.

摘要

最近使用质谱的研究发现了肌萎缩侧索硬化症 (ALS) 的候选生物标志物。然而,这些研究使用的 ALS 和对照受试者数量较少。需要使用更大的受试者队列进行额外的研究来验证这些候选生物标志物。通过质谱法检查了 100 名 ALS 患者、100 名疾病对照和 41 名健康对照的脑脊液 (CSF) 样本。61 个质谱峰在 ALS 和对照组之间表现出改变的水平。胱抑素 C 和转甲状腺素的质量峰在 ALS 中减少,而翻译后修饰的转甲状腺素和 C 反应蛋白 (CRP) 的质量峰增加。通过酶联免疫吸附法测定,对照组的 CRP 水平为 5.84 +/- 1.01ng/ml,ALS 组为 11.24 +/- 1.52ng/ml。这项研究验证了先前在 ALS 中胱抑素 C 和转甲状腺素的质谱结果。在 ALS 患者的 CSF 中 CRP 水平升高,并且胱抑素 C 水平与肢体发病患者的生存相关。我们的生物标志物谱预测 ALS 的总体准确性为 82%。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/f09c1c3c68e0/nihms237303f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/a0dddfa9d59a/nihms237303f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/e95a2f918d0b/nihms237303f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/cba2526417c1/nihms237303f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/f09c1c3c68e0/nihms237303f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/a0dddfa9d59a/nihms237303f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/e95a2f918d0b/nihms237303f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/cba2526417c1/nihms237303f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d70d/2975276/f09c1c3c68e0/nihms237303f4.jpg

相似文献

1
Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics.通过蛋白质组学发现和验证肌萎缩侧索硬化症的生物标志物。
Muscle Nerve. 2010 Jul;42(1):104-11. doi: 10.1002/mus.21683.
2
Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis.半胱氨酸蛋白酶抑制剂 C:肌萎缩侧索硬化症的候选生物标志物。
PLoS One. 2010 Dec 9;5(12):e15133. doi: 10.1371/journal.pone.0015133.
3
Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.肌萎缩侧索硬化症患者脑脊液中胱抑素C水平的测定。
Int J Clin Exp Pathol. 2015 May 1;8(5):5419-26. eCollection 2015.
4
Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis.脑脊液的蛋白质组分析鉴定出肌萎缩侧索硬化症的生物标志物。
J Neurochem. 2005 Dec;95(5):1461-71. doi: 10.1111/j.1471-4159.2005.03478.x.
5
Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.脑脊液的无标记液相色谱-串联质谱蛋白质组学分析确定了肌萎缩侧索硬化症的蛋白质/信号通路改变及候选生物标志物
J Proteome Res. 2015 Nov 6;14(11):4486-501. doi: 10.1021/acs.jproteome.5b00804. Epub 2015 Oct 8.
6
CSF cystatin C and diffusion tensor imaging parameters as biomarkers of upper motor neuron degeneration in amyotrophic lateral sclerosis.脑脊液胱抑素C和弥散张量成像参数作为肌萎缩侧索硬化症上运动神经元变性的生物标志物
Clin Neurol Neurosurg. 2018 Sep;172:162-168. doi: 10.1016/j.clineuro.2018.07.008. Epub 2018 Jul 10.
7
Cystatin C in cerebrospinal fluid as a biomarker of ALS.脑脊液中的胱抑素C作为肌萎缩侧索硬化症的生物标志物
Neurosci Lett. 2009 Mar 6;452(1):52-5. doi: 10.1016/j.neulet.2009.01.026.
8
Identification of potential CSF biomarkers in ALS.肌萎缩侧索硬化症潜在脑脊液生物标志物的鉴定
Neurology. 2006 Apr 25;66(8):1218-22. doi: 10.1212/01.wnl.0000203129.82104.07. Epub 2006 Feb 15.
9
Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis.用于诊断肌萎缩侧索硬化症的多种生物标志物组合的评估
BMC Neurol. 2016 Sep 15;16:173. doi: 10.1186/s12883-016-0689-x.
10
Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.肌萎缩侧索硬化症患者脑脊液中铁蛋白水平升高。
Acta Neurol Scand. 2017 Aug;136(2):145-150. doi: 10.1111/ane.12708. Epub 2016 Nov 1.

引用本文的文献

1
C-reactive protein: the nexus between inflammation and protein misfolding diseases.C反应蛋白:炎症与蛋白质错误折叠疾病之间的联系
Front Immunol. 2025 Jun 4;16:1612703. doi: 10.3389/fimmu.2025.1612703. eCollection 2025.
2
Gut microbiota immune cross-talk in amyotrophic lateral sclerosis.肠道微生物群与肌萎缩侧索硬化症的免疫交叉对话。
Neurotherapeutics. 2024 Oct;21(6):e00469. doi: 10.1016/j.neurot.2024.e00469. Epub 2024 Nov 6.
3
The Current Potential Pathogenesis of Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症当前潜在的发病机制

本文引用的文献

1
Decreased cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis.肌萎缩侧索硬化症患者脊髓运动神经元和星形胶质细胞中胱抑素C免疫反应性降低。
J Neuropathol Exp Neurol. 2009 Nov;68(11):1200-6. doi: 10.1097/NEN.0b013e3181bdcdce.
2
Applying proteomics to the diagnosis and treatment of ALS and related diseases.将蛋白质组学应用于肌萎缩侧索硬化症及相关疾病的诊断和治疗。
Muscle Nerve. 2009 Nov;40(5):753-62. doi: 10.1002/mus.21488.
3
Cystatin C in cerebrospinal fluid as a biomarker of ALS.脑脊液中的胱抑素C作为肌萎缩侧索硬化症的生物标志物
Mol Neurobiol. 2025 Jan;62(1):221-232. doi: 10.1007/s12035-024-04269-3. Epub 2024 Jun 3.
4
Cystatin C is associated with poor survival in amyotrophic lateral sclerosis patients.胱抑素C与肌萎缩侧索硬化症患者的不良生存状况相关。
Front Neurosci. 2024 Jan 5;17:1309568. doi: 10.3389/fnins.2023.1309568. eCollection 2023.
5
Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations.肌萎缩侧索硬化症的尿液生物标志物:候选物、机遇与考量
Brain Commun. 2023 Oct 24;5(6):fcad287. doi: 10.1093/braincomms/fcad287. eCollection 2023.
6
Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: Prospective cohort study.系统性炎症与随后发生的肌萎缩侧索硬化症风险:前瞻性队列研究。
Brain Behav Immun. 2023 Nov;114:46-51. doi: 10.1016/j.bbi.2023.07.026. Epub 2023 Aug 4.
7
Systemic inflammation and subsequent risk of amyotrophic lateral sclerosis: prospective cohort study.全身炎症与肌萎缩侧索硬化症的后续风险:前瞻性队列研究
medRxiv. 2023 Mar 10:2023.03.06.23286852. doi: 10.1101/2023.03.06.23286852.
8
Extracellular Vesicles as Potential Biomarkers in Amyotrophic Lateral Sclerosis.细胞外囊泡作为肌萎缩侧索硬化症的潜在生物标志物。
Genes (Basel). 2023 Jan 27;14(2):325. doi: 10.3390/genes14020325.
9
Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets.肌萎缩侧索硬化症中的炎症检查点:从生物标志物到治疗靶点。
Front Immunol. 2022 Dec 22;13:1059994. doi: 10.3389/fimmu.2022.1059994. eCollection 2022.
10
Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP.转甲状腺素蛋白通过激活自噬减轻 FTLD-TDP 中的 TDP-43 蛋白病,其途径为 ATF4。
Brain. 2023 May 2;146(5):2089-2106. doi: 10.1093/brain/awac412.
Neurosci Lett. 2009 Mar 6;452(1):52-5. doi: 10.1016/j.neulet.2009.01.026.
4
A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis.用于识别肌萎缩侧索硬化症患者的脑脊液生物标志物组合
Neurology. 2009 Jan 6;72(1):14-9. doi: 10.1212/01.wnl.0000333251.36681.a5. Epub 2008 Nov 5.
5
Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis.肌萎缩侧索硬化症患者的低度全身炎症
Acta Neurol Scand. 2009 Jun;119(6):383-9. doi: 10.1111/j.1600-0404.2008.01112.x. Epub 2008 Oct 23.
6
Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS).肌萎缩侧索硬化症(ALS)患者脑脊液的蛋白质组分析
Neurochem Res. 2008 Nov;33(11):2358-63. doi: 10.1007/s11064-008-9742-5. Epub 2008 May 15.
7
Protein biomarkers for amyotrophic lateral sclerosis.肌萎缩侧索硬化症的蛋白质生物标志物
Expert Rev Proteomics. 2008 Apr;5(2):249-62. doi: 10.1586/14789450.5.2.249.
8
EPO-KB: a searchable knowledge base of biomarker to protein links.EPO知识库:一个可搜索的生物标志物与蛋白质关联知识库。
Bioinformatics. 2008 Jun 1;24(11):1418-9. doi: 10.1093/bioinformatics/btn125. Epub 2008 Apr 9.
9
Inflammatory markers in AD and MCI patients with different biomarker profiles.具有不同生物标志物特征的阿尔茨海默病和轻度认知障碍患者的炎症标志物
Neurobiol Aging. 2009 Nov;30(11):1885-9. doi: 10.1016/j.neurobiolaging.2008.01.014. Epub 2008 Apr 18.
10
Cystatin C modulates cerebral beta-amyloidosis.胱抑素C调节脑内β-淀粉样变性。
Nat Genet. 2007 Dec;39(12):1437-9. doi: 10.1038/ng.2007.23. Epub 2007 Nov 18.